Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2018-01-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于公司获得三个医疗器械注册证的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1441 characters) from a company about obtaining three medical device registration certificates. It includes product information, impact on the company, and risk warnings. There are no financial statements, no detailed financial data, no management discussion, or regulatory certifications. The document is an official company announcement about regulatory approval of products, not a financial report or detailed filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2018-01-03 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the progress and details of using idle raised funds for cash management, including investment in low-risk financial products, approvals from board and shareholders, risk control measures, and related financial data. It does not contain a full financial report or detailed financial statements but rather updates on financing activities and fund management. The document length is 3811 characters, which is relatively short and focused on a specific financing-related activity. Therefore, it fits best under Capital/Financing Update (CAP) as it provides updates on the company's use of raised funds and cash management activities.
2017-12-15 Chinese
中信证券股份有限公司关于公司2017年持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年持续督导现场检查报告" which translates to "2017 Continuous Supervision On-site Inspection Report" by the sponsor (中信证券股份有限公司) for the company 厦门艾德生物医药科技股份有限公司. The content includes detailed governance, internal control, information disclosure, related party transactions, use of raised funds, performance, and compliance checks. It is a detailed inspection report focusing on regulatory compliance and internal controls rather than a full annual or quarterly financial report. It does not contain typical financial statements or earnings highlights, nor is it a simple announcement or certification. The document is a standalone audit or inspection report related to regulatory supervision and internal controls, fitting the category of Audit Report / Information (AR). FY 2017
2017-12-14 Chinese
关于公司获得政府补助的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (792 characters) about the company receiving a government subsidy of 2.8 million RMB. It explains the nature of the subsidy, accounting treatment, and expected impact on profit. There are no financial statements or detailed financial data presented. The document is an announcement of a financing-related event (government grant) rather than a full financial report or audit. It does not fit categories like Annual Report, Interim Report, or Audit Report. It is not a regulatory certification or voting result. The best fitting category is Capital/Financing Update (CAP) because it informs about a capital-related event (government subsidy) impacting the company's finances. Confidence is high given the clear content and short length indicating an announcement rather than a full report.
2017-12-14 Chinese
中信证券股份有限公司关于公司2017年持续督导培训情况的报告
Regulatory Filings Classification · 95% confidence The document is a report from CITIC Securities regarding the 2017 continuous supervision training conducted for Xiamen Aide Biomedical Technology Co., Ltd. It details the training session's basic information, participants, content, and conclusions. The document is relatively short (1350 characters) and focuses on regulatory compliance training rather than financial results or corporate governance changes. It is not an annual report, audit report, earnings release, or management report. It is also not a simple announcement of a report but a detailed report on a specific regulatory training activity. This type of document aligns best with Regulatory Filings (RNS) as it is a compliance-related report submitted to the Shenzhen Stock Exchange, not fitting other more specific categories.
2017-12-14 Chinese
关于公司获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of government subsidies related to a specific project. It details the amount received, the accounting treatment, and the expected impact on profits. There is no indication that this is a full financial report, audit report, or earnings release. The document is relatively short (874 characters) and serves as a regulatory announcement about government funding received, which affects financials but is not a comprehensive financial report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about government subsidies and their accounting treatment, without substantive financial statements or detailed analysis.
2017-11-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.